User menu

How to select a nanosimilar.

Bibliographic reference Astier, Alain ; Barton Pai, Amy ; Bissig, Marco ; Crommelin, Daan J A ; Flühmann, Beat ; et. al. How to select a nanosimilar.. In: Annals / New York Academy of Sciences, Vol. 1407, no. 1, p. 50-65 (2017)
Permanent URL
  1. Noorlander Cornelle W, Kooi Myrna W, Oomen Agnes G, Park Margriet VDZ, Vandebriel Rob J, Geertsma Robert E, Horizon scan of nanomedicinal products, 10.2217/nnm.15.21
  2. Ehmann, GaBI, 5, 1 (2016)
  3. Crommelin, AAPS Advances in the Pharmaceutical Sciences Series (2015)
  4. Ehmann Falk, Sakai-Kato Kumiko, Duncan Ruth, Pérez de la Ossa Dolores Hernán, Pita Ruben, Vidal Jean-Marc, Kohli Ashish, Tothfalusi Laszlo, Sanh Alan, Tinton Sandrine, Robert Jean-Louis, Silva Lima Beatriz, Amati Marisa Papaluca, Next-generation nanomedicines and nanosimilars: EU regulators’ initiatives relating to the development and evaluation of nanomedicines, 10.2217/nnm.13.68
  5. Rottembourg J., Kadri A., Leonard E., Dansaert A., Lafuma A., Do two intravenous iron sucrose preparations have the same efficacy?, 10.1093/ndt/gfr024
  6. Agüera Maria Luisa, Martin-Malo Alejandro, Alvarez-Lara Maria Antonia, Garcia-Montemayor Victoria Eugenia, Canton Petra, Soriano Sagrario, Aljama Pedro, Efficiency of Original versus Generic Intravenous Iron Formulations in Patients on Haemodialysis, 10.1371/journal.pone.0135967
  7. Lee Eun Sil, Park Bo Ra, Kim Jeong Sig, Choi Gyu Yeon, Lee Jeong Jae, Lee Im Soon, Comparison of adverse event profile of intravenous iron sucrose and iron sucrose similar in postpartum and gynecologic operative patients, 10.1185/03007995.2012.760444
  8. Stein Jürgen, Dignass Axel, Chow Kai Uwe, Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator, 10.1185/03007995.2011.651527
  9. Martin-Malo A., Merino A., Carracedo J., Alvarez-Lara M. A., Ojeda R., Soriano S., Crespo R., Ramirez R., Aljama P., Effects of intravenous iron on mononuclear cells during the haemodialysis session, 10.1093/ndt/gfr711
  10. European Medicines Agency 2015 Reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product
  11. European Medicines Agency 2013 Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product
  12. U.S. Food and Drug Administration 2015 Liposome drug products-guidance for industry
  13. Crommelin Daan J. A., de Vlieger Jon S. B., Weinstein Vera, Mühlebach Stefan, Shah Vinod P., Schellekens Huub, Different Pharmaceutical Products Need Similar Terminology, 10.1208/s12248-013-9532-0
  14. European Commission 2013 What you need to know about biosimilar medicinal products
  15. European Medicines Agency 2014 Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues
  16. European Medicines Agency 2014 Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues
  17. Knoeff Josefien, Flühmann Beat, Mühlebach Stefan, Medication practice in hospitals: are nanosimilars evaluated and substituted correctly?, 10.1136/ejhpharm-2016-001059
  18. Schellekens Huub, Stegemann Sven, Weinstein Vera, de Vlieger Jon S. B., Flühmann Beat, Mühlebach Stefan, Gaspar Rogério, Shah Vinod P., Crommelin Daan J. A., How to Regulate Nonbiological Complex Drugs (NBCD) and Their Follow-on Versions: Points to Consider, 10.1208/s12248-013-9533-z
  19. Griffith Niesha, McBride Ali, Stevenson James, Green Larry, Formulary Selection Criteria for Biosimilars: Considerations for US Health-System Pharmacists, 10.1310/hpj4909-813
  20. Boone Niels, Kuy Hugo van der, Scott Mike, Mairs Jill, Krämer Irene, Vulto Arnold, Janknegt Rob, How to select a biosimilar, 10.1136/ejhpharm-2013-000370
  21. Li , E.C. J.G. Stevenson 2015 Biosimilars-the time is now: challenges and opportunities for pharmacists (abstract)
  22. Epstein-Barash Hila, Gutman Dikla, Markovsky Ela, Mishan-Eisenberg Galit, Koroukhov Nickolay, Szebeni Janos, Golomb Gershon, Physicochemical parameters affecting liposomal bisphosphonates bioactivity for restenosis therapy: Internalization, cell inhibition, activation of cytokines and complement, and mechanism of cell death, 10.1016/j.jconrel.2010.03.011
  23. Storm Gert, Belliot Sheila O., Daemen Toos, Lasic Danilo D., Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system, 10.1016/0169-409x(95)00039-a
  24. Doane Tennyson L., Burda Clemens, The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapy, 10.1039/c2cs15260f
  25. Moghimi S. M., Nanomedicine: current status and future prospects, 10.1096/fj.04-2747rev
  26. Hirn Stephanie, Semmler-Behnke Manuela, Schleh Carsten, Wenk Alexander, Lipka Jens, Schäffler Martin, Takenaka Shinji, Möller Winfried, Schmid Günter, Simon Ulrich, Kreyling Wolfgang G., Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration, 10.1016/j.ejpb.2010.12.029
  27. Cheng Yu, C. Samia Anna, Meyers Joseph D., Panagopoulos Irene, Fei Baowei, Burda Clemens, Highly Efficient Drug Delivery with Gold Nanoparticle Vectors forin VivoPhotodynamic Therapy of Cancer, 10.1021/ja801631c
  28. Chertow G. M., Mason P. D., Vaage-Nilsen O., Ahlmen J., On the relative safety of parenteral iron formulations, 10.1093/ndt/gfh185
  29. Bailie G. R., Comparison of rates of reported adverse events associated with i.v. iron products in the United States, 10.2146/ajhp110262
  30. Heurtault B, Physico-chemical stability of colloidal lipid particles, 10.1016/s0142-9612(03)00331-4
  31. Geisser Peter, Burckhardt Susanna, The Pharmacokinetics and Pharmacodynamics of Iron Preparations, 10.3390/pharmaceutics3010012
  32. Brookhart M. A., Freburger J. K., Ellis A. R., Wang L., Winkelmayer W. C., Kshirsagar A. V., Infection Risk with Bolus versus Maintenance Iron Supplementation in Hemodialysis Patients, 10.1681/asn.2012121164
  33. Pai Amy Barton, Boyd Alex V, McQuade Charles R, Harford Antonia, Norenberg Jeffrey P, Zager Philip G, Comparison of Oxidative Stress Markers After Intravenous Administration of Iron Dextran, Sodium Ferric Gluconate, and Iron Sucrose in Patients Undergoing Hemodialysis, 10.1592/phco.27.3.343
  34. Smith Judith A., Mathew Lata, Burney Maryam, Nyshadham Pranavanand, Coleman Robert L., Equivalency challenge: Evaluation of Lipodox® as the generic equivalent for Doxil® in a human ovarian cancer orthotropic mouse model, 10.1016/j.ygyno.2016.02.033
  35. Smith Judith A, Costales Anthony B, Jaffari Mona, Urbauer Diana L, Frumovitz Michael, Kutac Christine K, Tran Huyentran, Coleman Robert L, Is it equivalent? Evaluation of the clinical activity of single agent Lipodox® compared to single agent Doxil® in ovarian cancer treatment, 10.1177/1078155215594415
  36. Berger, Oncol. Targets Ther., 7, 1409 (2014)
  37. Desai Neil, Challenges in Development of Nanoparticle-Based Therapeutics, 10.1208/s12248-012-9339-4
  38. Toblli Jorge E., Cao Gabriel, Angerosa Margarita, Nitrosative stress and apoptosis in non-anemic healthy rats induced by intravenous iron sucrose similars versus iron sucrose originator, 10.1007/s10534-015-9822-3
  39. Porter Christopher J.H., Moghimi S.Moein, Illum Lisbeth, Davis Stanley S., The polyoxyethylene/polyoxypropylene block co-polymer Poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow, 10.1016/0014-5793(92)80655-z
  40. European Medicines Agency 2011 Reflection paper on non-clinical studies for generic nanoparticle iron medicinal product applications
  41. U.S. Food and Drug Administration 2013 Draft guidance on iron sucrose
  42. Philipp Erik, Braitsch Michaela, Bichsel Tobias, Mühlebach Stefan, Diluting ferric carboxymaltose in sodium chloride infusion solution (0.9% w/v) in polypropylene bottles and bags: effects on chemical stability, 10.1136/ejhpharm-2015-000697